Fujirebio is a global leader in high-quality in vitro diagnostics (IVD), dedicated to developing innovative technologies and biomarkers with significant clinical value. Founded in Tokyo in 1950, Fujirebio has grown through strategic acquisitions, including Centocor Diagnostics, CanAg Diagnostics, and Innogenetics, expanding its IVD expertise. With offices across Japan, Asia, Europe, and the Americas, the company collaborates with global healthcare partners to provide diagnostic solutions spanning from specialized to fully automated clinical testing. As a subsidiary of H.U. Group Holdings, Fujirebio employs over 1,200 people worldwide, focusing on advancing healthcare by meeting diagnostic needs efficiently.